Otilimab (GSK 3196165) is an humanized monoclonal antibody targeting GM-CSF (granulocyte-macrophage colony-stimulating factor). Otilimab neutralises the biological function of GM-CSF by blocking the interaction of GM-CSF with its cell surface receptor. MW: 145.5 KD.